Roivant unit Genevant, Arbutus file patent infringement suits against Pfizer, BioNTech over LNP technology
PUBT · 22h ago
Share
Listen to the news
- Roivant unit Genevant joined Arbutus in filing patent infringement suits against Pfizer, BioNTech over lipid nanoparticle technology used in mRNA COVID-19 vaccines.
- Actions target patents including Canadian Patent No. 2,721,333, EP 4 241 767, EP 4 495 237, seeking damages and injunctions.
- Arbutus received USD 178 million from Moderna under a March 2026 settlement over LNP patents.
- Arbutus plans up to about USD 230 million in share repurchases starting in Q3 2026, contingent on a Genevant-related dividend.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved